X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (88) 88
oncology (86) 86
female (70) 70
index medicus (70) 70
male (69) 69
middle aged (68) 68
aged (66) 66
lung neoplasms - drug therapy (51) 51
adult (47) 47
aged, 80 and over (38) 38
article (37) 37
carcinoma, non-small-cell lung - drug therapy (37) 37
cancer (34) 34
lung neoplasms - pathology (30) 30
treatment outcome (30) 30
chemotherapy (29) 29
tumors (25) 25
immunotherapy (24) 24
lung cancer (24) 24
lung cancer, non-small cell (24) 24
antineoplastic agents - therapeutic use (23) 23
neoplasm staging (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
peptides (21) 21
lung neoplasms - genetics (20) 20
carcinoma, non-small-cell lung - pathology (19) 19
docetaxel (19) 19
cell lung-cancer (18) 18
chemistry (18) 18
human necessities (18) 18
hygiene (18) 18
medical or veterinary science (18) 18
metallurgy (18) 18
organic chemistry (18) 18
preparations for medical, dental, or toilet purposes (18) 18
respiratory system (18) 18
care and treatment (17) 17
dose-response relationship, drug (17) 17
lung neoplasms - mortality (17) 17
mutation (17) 17
nivolumab (17) 17
survival rate (17) 17
therapy (17) 17
gefitinib (16) 16
neoplasms - drug therapy (16) 16
research (16) 16
adenocarcinoma - drug therapy (15) 15
carcinoma, non-small-cell lung - mortality (15) 15
trial (14) 14
antineoplastic agents - adverse effects (13) 13
carcinoma, non-small-cell lung - genetics (13) 13
drug administration schedule (13) 13
mutations (13) 13
patients (13) 13
safety (13) 13
antibodies, monoclonal - therapeutic use (12) 12
ipilimumab (12) 12
pharmacology & pharmacy (12) 12
prognosis (12) 12
adenocarcinoma - pathology (11) 11
disease-free survival (11) 11
erlotinib (11) 11
melanoma (11) 11
survival (11) 11
adenocarcinoma - genetics (10) 10
cohort studies (10) 10
drug therapy (10) 10
infusions, intravenous (10) 10
maximum tolerated dose (10) 10
survival analysis (10) 10
abridged index medicus (9) 9
apoptosis (9) 9
beer (9) 9
bevacizumab (9) 9
biochemistry (9) 9
compositions or test papers therefor (9) 9
condition-responsive control in microbiological orenzymological processes (9) 9
disease progression (9) 9
enzymology (9) 9
expression (9) 9
growth (9) 9
lung neoplasms - metabolism (9) 9
measuring or testing processes involving enzymes, nucleicacids or microorganisms (9) 9
microbiology (9) 9
mutation or genetic engineering (9) 9
non-small cell lung cancer (9) 9
processes of preparing such compositions (9) 9
quinazolines - administration & dosage (9) 9
quinazolines - therapeutic use (9) 9
receptor, epidermal growth factor - genetics (9) 9
solid tumors (9) 9
specific therapeutic activity of chemical compounds ormedicinal preparations (9) 9
spirits (9) 9
vinegar (9) 9
wine (9) 9
antibodies, monoclonal - adverse effects (8) 8
antineoplastic agents - administration & dosage (8) 8
cancer therapies (8) 8
cisplatin (8) 8
erlotinib hydrochloride (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 299 - 308
Journal Article
Journal Article
Science, ISSN 0036-8075, 03/2016, Volume 351, Issue 6280, pp. 1463 - 1469
Journal Article
Science, ISSN 0036-8075, 04/2015, Volume 348, Issue 6230, pp. 124 - 128
Immune checkpoint inhibitors, which unleash a patient's own T cells to kill tumors, are revolutionizing cancer treatment. To unravel the genomic determinants... 
RESPONSES | EPITOPE | ADVANCED MELANOMA | MULTIDISCIPLINARY SCIENCES | ANTIBODY | ANTIGENS | NIVOLUMAB | EXOME ANALYSIS REVEALS | T-CELLS | IPILIMUMAB | MPDL3280A | Genetic aspects | Gene mutations | Lung cancer, Non-small cell | Identification and classification | Lung cancer | Mutation | Mutations | Therapy | Effectiveness | Lungs | Palladium | Patients | Tumors | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 257 - 265
Journal Article
Nature, ISSN 0028-0836, 11/2017, Volume 551, Issue 7681, pp. 517 - 520
Checkpoint blockade immunotherapies enable the host immune system to recognize and destroy tumour cells(1). Their clinical activity has been correlated with... 
CELL LUNG-CANCER | CTLA-4 BLOCKADE | MELANOMA | THERAPY | LANDSCAPE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | RESISTANCE | CLINICAL-RESPONSE | REPERTOIRES | Humans | Lung Neoplasms - pathology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antigen Presentation | Melanoma - genetics | Immunotherapy | Cell Cycle Checkpoints - genetics | Cell Cycle Checkpoints - immunology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Antigens, Neoplasm - genetics | Antigens, Neoplasm - immunology | Carcinoma, Non-Small-Cell Lung - genetics | Lymphocyte Activation | CTLA-4 Antigen - genetics | Lung Neoplasms - therapy | Melanoma - pathology | CTLA-4 Antigen - immunology | Carcinoma, Non-Small-Cell Lung - immunology | Carcinoma, Non-Small-Cell Lung - therapy | Lung Neoplasms - immunology | Models, Immunological | Melanoma - immunology | Survival Analysis | T-Lymphocytes - immunology | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Melanoma - therapy | Programmed Cell Death 1 Receptor - genetics | Cohort Studies | Evolution, Molecular | Antigens | Care and treatment | Patient outcomes | Models | Health aspects | Tumors | Medical research | Peptides | PD-1 protein | Lung cancer | Melanoma | Cytotoxicity | Lymphocytes T | Patients | Proteins | Cell recognition | CTLA-4 protein | Major histocompatibility complex | Immune checkpoint | Lymphocytes | Evolution | Mutation | Histocompatibility | Cancer | Immune system | Fitness
Journal Article
JAMA, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1600 - 1609
Journal Article
Nature Genetics, ISSN 1061-4036, 02/2019, Volume 51, Issue 2, pp. 202 - 206
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer... 
CTLA-4 BLOCKADE | THERAPY | LANDSCAPE | PD-1 BLOCKADE | GENETICS & HEREDITY | SENSITIVITY | NEOANTIGENS | Usage | Research | Gene mutations | Immunotherapy | Oncology, Experimental | Cancer | Laboratories | Lung cancer | Melanoma | Histology | Metastasis | Gene expression | Cancer therapies | Patients | Survival | Metastases | Next-generation sequencing | Immune checkpoint | Biomarkers | Mutation | Tumors
Journal Article
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment
Journal Article